Canopy Growth Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos de Canopy Growth disminuyan en un 4.4% al año, mientras que se espera que sus beneficios anuales crezcan en un 84.6% al año. Se prevé que el BPA crezca en un 90.9% anual. Se prevé que la rentabilidad financiera sea de -5.5% en 3 años.

Información clave

84.6%

Tasa de crecimiento de los beneficios

93.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.9%
Tasa de crecimiento de los ingresos	-3.6%
Rentabilidad financiera futura	-2.1%
Cobertura de analistas	Good
Última actualización	07 May 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Canopy Growth Set For U.S. Cannabis Markets

Apr 26

Canopy Growth Is Climbing, But It Won't Last

Mar 22

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Feb 06

Canopy gains 12% to lead Canadian cannabis rally as former Aphria legal chief joins

Aug 02

Canopy Growth: Constellation's Investment Goes Up In Smoke

Jul 18

Canopy Growth: Bankruptcy Risks Are Growing Like A Weed

Jun 28

Canopy Growth: Still Not At Rock Bottom

May 27

Can Canopy Growth's Stock Price Recover To $10?

May 04

Canopy Growth: Can Wana Save The Day?

Mar 24

Canopy Growth: Insight Into Upcoming Q3-2022 Earnings

Feb 08

Canopy Growth: 5 Lessons From The Pot Bubble Burst

Dec 27

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:CGC - Estimaciones futuras de los analistas y datos financieros pasados (CAD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	358	-55	20	-23	1
3/31/2026	325	-113	-20	-62	4
3/31/2025	303	-121	-117	-65	10
3/31/2024	321	-491	-216	-223	12
12/31/2023	362	-1,180	-407	-400	N/A
9/30/2023	369	-1,172	-520	-511	N/A
6/30/2023	387	-1,221	-576	-566	N/A
3/31/2023	403	-3,278	-568	-558	N/A
12/31/2022	367	-3,051	-559	-544	N/A
9/30/2022	423	-2,938	-583	-568	N/A
6/30/2022	466	-2,766	-550	-521	N/A
3/31/2022	510	-310	-594	-546	N/A
12/31/2021	557	-428	-587	-517	N/A
9/30/2021	569	-1,223	-552	-437	N/A
6/30/2021	572	-1,244	-644	-513	N/A
3/31/2021	547	-1,745	-622	-466	N/A
12/31/2020	506	-2,348	-803	-579	N/A
9/30/2020	477	-1,535	-1,033	-681	N/A
6/30/2020	419	-1,244	-1,282	-733	N/A
3/31/2020	399	-1,321	-1,495	-773	N/A
12/31/2019	385	-415	-1,610	-802	N/A
9/30/2019	344	-256	-1,578	-709	N/A
6/30/2019	291	-832	-1,408	-626	N/A
3/31/2019	226	-736	-1,254	-535	N/A
12/31/2018	155	-398	-958	-332	N/A
9/30/2018	94	-464	-709	-257	N/A
6/30/2018	88	-148	-462	-137	N/A
3/31/2018	78	-67	-260	-82	N/A
12/31/2017	70	-21	-160	-60	N/A
9/30/2017	58	-19	N/A	-41	N/A
6/30/2017	49	-13	N/A	-36	N/A
3/31/2017	40	-8	N/A	-27	N/A
12/31/2016	30	-1	N/A	-14	N/A
9/30/2016	24	-7	N/A	-15	N/A
6/30/2016	18	-8	N/A	-14	N/A
3/31/2016	13	-3	N/A	-14	N/A
12/31/2015	8	0	N/A	-14	N/A
9/30/2015	6	1	N/A	-12	N/A
6/30/2015	3	-5	N/A	-10	N/A
3/31/2015	2	-7	N/A	-9	N/A
12/31/2014	1	-9	N/A	-10	N/A
9/30/2014	1	-7	N/A	-8	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CGC siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CGC siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CGC siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de CGC disminuyan en los próximos 3 años (-4.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de CGC disminuyan en los próximos 3 años (-4.4% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: CGC se prevé que no sea rentable en 3 años.

Canopy Growth Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Canopy Growth Corporation (TSX:WEED) exercised its option to acquire Wana Brands for $300 million.

Canopy Growth Set For U.S. Cannabis Markets

Less than half of directors are independent

Canopy Growth Corporation Announces Board and Committee Changes

New major risk - Share price stability

Canopy Growth Is Climbing, But It Won't Last

Canopy Growth Launches New Pre-Rolls from 7Acres and Hiway

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Canopy Growth Corporation Announces Board Changes

New major risk - Revenue and earnings growth

Bioriginal Food & Science Corporation acquired KeyLeaf Life Sciences from Canopy Growth Corporation (TSX:WEED).

Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come

Canopy Growth: Further Implosion Is Now A Matter Of When Not If

Canopy Growth Corporation Announces the Introduction of New Product Offerings Across the Company's Adult Use and Medical Cannabis Portfolio

Canopy Growth Corporation announced that it expects to receive $35.000008 million in funding

Avoid Canopy Growth After Failed Equity Sale

Canopy Growth Corporation to Report Q3, 2024 Results on Feb 09, 2024

Canopy Growth Corporation announced that it expects to receive $30 million in funding

Inspirit Management Ltd acquired This Works Products Limited from Canopy Growth Corporation (TSX:WEED) for £9.3 million.

Canopy Growth Corporation Partners with Marquee Brands Partners and Martha Stewart CBD to Unveil New Line of Need-Based CBD Gummies

New minor risk - Insider selling

Canopy Growth Corporation Announces the Addition of Four New Flower Product Offerings from Iconic Brands 7ACRES and Tweed

New major risk - Financial position

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Canopy Growth Corporation announced that it expects to receive $24.99312 million in funding

Canopy Growth Corporation announced that it expects to receive $24.99312 million in funding

Canopy Growth Corporation Announces Addition of Five New Pre-Roll Flower Product Offerings from Iconic Brands Tweed, 7ACRES, and for the First Time, from Spectrum Therapeutics

Canopy Growth Corporation Announces Executive Changes

Canopy Growth Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Canopy Growth Corporation, Annual General Meeting, Sep 25, 2023

Lieff Cabraser Heimann & Bernstein, LLP Announces Class Action Lawsuit on Behalf of the Investors in Canopy Growth Corporation Who Suffered Losses from Purchasing or Otherwise Acquiring Canopy Securities Between June 1, 2021 and May 10, 2023

An unknown buyer acquired a Facility in Modesto, CA from Canopy Growth Corporation (TSX:WEED).

Canopy Growth Corporation to Report Q4, 2023 Results on Jun 22, 2023

Canopy Growth Corporation announced delayed amended 10-K filing

Canopy Growth Corporation announced delayed annual 10-K filing

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Canopy Growth Corporation

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

420 Investments Ltd. acquired Five Retail Locations in Alberta from Canopy Growth Corporation (TSX:WEED).

Canopy Growth Corporation Announces Termination of Julious Grant as Chief Commercial Officer, Effective December 16, 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Canopy Growth Corporation (TSX:WEED) acquired Manufacturing facility in USA.

Canopy Growth Corporation Announces Extension of Its Ace Valley Brand Portfolio with the Launch of Lust Cherry Rose and Thrust Watermelon Goji

Canopy Growth (Nasdaq:CGC): Further Dilution Seems Inevitable

Canopy Growth: Getting High

Quick Takes: Tesla, Twitter, Carvana & More

420 Investments Ltd. agreed to acquire Five Retail Locations in Alberta from Canopy Growth Corporation (TSX:WEED).

Canopy Growth to sell Canadian retail operations, including Tokyo Smoke stores

Canopy Growth: BioSteel Sizzles, Everything Else Fizzles

What Is Canopy Growth's Stock Outlook After Earnings Miss?

Limited-Edition Pumpkin Spice CBD Wellness Gummies™ Arrive Just in Time for Fall As Martha Stewart CBD Expands Portfolio

Canopy Growth leads cannabis rally as Senator backs compromise legislation

Canopy Growth Corporation Appoints Christelle Gedeon as Chief Legal Officer

Canopy gains 12% to lead Canadian cannabis rally as former Aphria legal chief joins

Canopy Growth Corporation Announces New Premium Flower Line-Up

Canopy Growth: Constellation's Investment Goes Up In Smoke

Canopy Growth Corporation Celebrates Summer with New 'Just Hits Different' Beverage Campaign

Canopy Growth: Bankruptcy Risks Are Growing Like A Weed

Canopy Growth Corporation to Report Q3, 2023 Results on Feb 09, 2023

Canopy Growth Corporation to Report Q2, 2023 Results on Nov 09, 2022

Canopy Growth Corporation, Annual General Meeting, Sep 15, 2022

Canopy Growth: Still Not At Rock Bottom

Canopy Growth Corporation unveils Line-Up of New Offerings Across Its Premium Brand Portfolio – 7ACRES, Ace Valley, Deep Space and Doja

Can Canopy Growth's Stock Price Recover To $10?

Canopy Growth Corporation Provides Non-Cash Impairment Charges Guidance for the Fourth Quarter of 2022

Canopy Growth Corporation to Report Q4, 2022 Results on May 27, 2022

Canopy Growth Unveils Behind the Scenes Look at 7Acres' Premium Flower Production

Canopy Growth Corporation Appoints Judy Hong as Chief Financial Officer

Canopy Growth: Can Wana Save The Day?

Canopy Growth: Insight Into Upcoming Q3-2022 Earnings

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Dermapharm Holding SE (XTRA:DMP) completed the acquisition of C³ - Cannabinoid Compound Company Gmbh from Canopy Growth Corporation (TSX:WEED).

Canopy Growth Corporation Unveils the Next Chapter of the Tweed Brand with the Launch of New Products, Formats, and A Refresh of the Brand's Look and Feel

Martha Stewart CBD Launches its First-Ever Category Expansion with New Line of CBD Wellness Topicals

Canopy Growth: 5 Lessons From The Pot Bubble Burst